Oh god... Stoney's in the house now. Here comes the morning blitz of cut and pastes from Yahoo and Seeking Alpha. Time to hand the microphone to the drummer, let him have a little fun.
Van I am having an argument with the HF I know I told them to buy Wallmart but I can't find the email.
-> Time To Roll The Dice (again) -? Dice Therapeutics initiated with a Buy at Guggenheim 06:33 DICE Guggenheim analyst Seamus Fernandez initiated coverage of Dice Therapeutics with a Buy rating and $65 price target. Dice's lead compound, DC-806, recently achieved early clinical proof of concept, which Fernandez calls "a potential breakthrough in industry-wide efforts targeting IL-17." The analyst, who sees "multibillion-dollar potential" for DC-806, thinks a three-times or greater return could perhaps be "catalyzed by a major global partnership or M&A event" should Phase 1 results for DC-853 imply once-daily best-in-class potential in its 2023 readout and Phase 2b results show efficacysimilar to Cosentyx, Fernandez tells investors.
X-Ray reveals lack of earnings. Dentsply Sirona reports Q3 adjusted EPS 41c, consensus 57c 15:25 XRAY Reports Q3 revenue $947M, consensus $1.03B. "Our third quarter results reflect continued macroeconomic headwinds, including foreign currency impacts, global supply chain challenges, and regional softness in the U.S. and China. Despite the challenges this quarter, we were encouraged by double-digit growth in clear aligners, solid performance in Europe, and continued strong demand for Imaging equipment," said Simon Campion, Chief Executive Officer. "We are not satisfied with third quarter results, however this quarter marks an important turning point as we enter our company's next chapter. We have initiated a comprehensive review of our entire business in order to improve our execution, build a winning portfolio, and return the Company to growth. Dentsply Sirona has great products and solutions, a healthy innovation pipeline, and we are committed to charting a path forward which delivers better and more consistent results for our shareholders."
Watch Carefully $41 area needs to be cleared for run to $45 Evoqua Water GAAP EPS of $0.33 beats by $0.03, revenue of $504.76M beats by $39.38M Nov. 15, 2022 7:04 AM ET Evoqua Water Technologies Corp. (AQUA) Evoqua Water (NYSE:AQUA): Q4 GAAP EPS of $0.33 beats by $0.03.
Ginkgo Bioworks down 7% as it sees fewer new cell programs, lower Foundry revenue range Cathie boots another one... I like the old pictures of her a lot better, feel the same way about myself.